Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?

This highflier has fallen on hard times recently. Moderna Therapeutics (MRNA -2.01%) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine. While COVID has not gone away, the virus is no longer top of mind, and fewer people feel the need to update their vaccination for the illness. With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Inv ...